JAK2 Inhibitor, Fedratinib, Inhibits P-gp Activity and Co-Treatment Induces Cytotoxicity in Antimitotic Drug-Treated P-gp Overexpressing Resistant KBV20C Cancer Cells

P-glycoprotein (P-gp) overexpression is one of the major mechanisms of multidrug resistance (MDR). Previously, co-treatment with Janus kinase 2 (JAK2) inhibitors sensitized P-gp-overexpressing drug-resistant cancer cells. In this study, we assessed the cytotoxic effects of JAK2 inhibitor, fedratinib...

Descripción completa

Detalles Bibliográficos
Autores principales: Oh, Yunmoon, Lee, Jin-Sol, Lee, Ji Sun, Park, Jae Hyeon, Kim, Hyung Sik, Yoon, Sungpil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9100550/
https://www.ncbi.nlm.nih.gov/pubmed/35562984
http://dx.doi.org/10.3390/ijms23094597

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9100550/
https://www.ncbi.nlm.nih.gov/pubmed/35562984
http://dx.doi.org/10.3390/ijms23094597

Ejemplares similares